Abiraterone acetate/antiandrogens: Paraneoplastic Cushing syndrome secondary to neuroendocrine prostate cancer: case report.

A man in his 70s [ I exact age not stated i ] developed paraneoplastic Cushing syndrome secondary to neuroendocrine prostate cancer following treatment with abiraterone acetate and unspecified anti-androgen therapy for metastatic castration resistant prostate cancer (mCRPC) [ I routes, dosages and times to reactions onsets not stated i ]. B Author comment: b I "Treatment-emergent neuroendocrine prostate cancer has become increasingly more common owing to the development of second-generation anti-hormonal therapy." Paraneoplastic Syndrome Secondary to Treatment Emergent Neuroendocrine Tumor in Metastatic Castration-resistant Prostate Cancer: A Unique Case. [Extracted from the article]